Barclays PLC Cassava Sciences Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Barclays PLC holds 74,747 shares of SAVA stock, worth $213,028. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,747

Previous 74,747 -0.0%

Holding current value

$213,028

Previous $2.2 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$9.57 - $35.08 $511,870 - $1.88 Million	53,487 Added 251.59%	74,747 $2.2 Million
Q2 2024 Aug 14, 2024	SELL	$12.35 - $26.11 $371,710 - $785,858	-30,098 Reduced 58.6%	21,260 $264,000
Q1 2024 May 15, 2024	SELL	$18.44 - $26.41 $1 Million - $1.43 Million	-54,232 Reduced 51.36%	51,358 $1.04 Million
Q4 2023 Feb 15, 2024	BUY	$12.64 - $30.11 $997,144 - $2.38 Million	78,888 Added 295.44%	105,590 $2.38 Million
Q3 2023 Nov 07, 2023	BUY	$16.64 - $25.32 $111,671 - $169,922	6,711 Added 33.57%	26,702 $445,000
Q2 2023 Aug 03, 2023	SELL	$21.59 - $27.88 $270,090 - $348,778	-12,510 Reduced 38.49%	19,991 $489,000
Q1 2023 May 04, 2023	SELL	$23.46 - $36.44 $261,696 - $406,488	-11,155 Reduced 25.55%	32,501 $783,000
Q4 2022 Feb 13, 2023	BUY	$27.82 - $44.16 $615,211 - $976,554	22,114 Added 102.66%	43,656 $1.29 Million
Q3 2022 Nov 03, 2022	BUY	$16.33 - $51.06 $14,729 - $46,056	902 Added 4.37%	21,542 $901,000
Q2 2022 Aug 12, 2022	SELL	$17.22 - $38.47 $62,353 - $139,299	-3,621 Reduced 14.93%	20,640 $581,000
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $2.83 Million - $4.6 Million	-86,747 Reduced 78.14%	24,261 $901,000
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $1.99 Million - $4.93 Million	54,207 Added 95.43%	111,008 $4.85 Million
Q3 2021 Nov 09, 2021	BUY	$41.79 - $135.3 $2.17 Million - $7.03 Million	51,960 Added 1073.33%	56,801 $3.53 Million
Q2 2021 Aug 13, 2021	SELL	$32.15 - $89.72 $723,085 - $2.02 Million	-22,491 Reduced 82.29%	4,841 $414,000
Q1 2021 May 13, 2021	BUY	$7.09 - $87.95 $118,530 - $1.47 Million	16,718 Added 157.51%	27,332 $1.23 Million
Q4 2020 Feb 11, 2021	SELL	$6.79 - $12.25 $448 - $808	-66 Reduced 0.62%	10,614 $72,000
Q3 2020 Nov 12, 2020	SELL	$2.86 - $11.51 $53,201 - $214,109	-18,602 Reduced 63.53%	10,680 $122,000
Q2 2020 Aug 12, 2020	BUY	$2.04 - $9.64 $59,735 - $282,278	29,282 New	29,282 $91,000

Others Institutions Holding SAVA

# of Institutions

207

Shares Held

14M

Call Options Held

2.98M

Put Options Held

6.57M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $114M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account